| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
74,043,000 |
| Market
Cap: |
86.63(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6449 - $10.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.6 |
| Insider 6 Months : 4.6 |
| Insider 3/6 Months : 9.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aclaris Therapeutics is a biopharmaceutical company that develops drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes Zunsemetinib, which is for the indication of rheumatoid arthritis (moderate to severe), psoriatic arthritis (moderate to severe), and hidradenitis suppurativa (moderate to severe); ATI-1777, which is for the indication of atopic dermatitis (moderate to severe); ATI-2138, which is for the indication of T cell-mediated autoimmune diseases; Gut-Biased Program, which is for the indication of inflammatory bowel disease; and ATI-2231, which is for the indication of metastatic breast cancer and pancreatic cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
14,500 |
14,500 |
38,695 |
51,495 |
| Total Buy Value |
$17,955 |
$17,955 |
$192,885 |
$292,695 |
| Total People Bought |
1 |
1 |
3 |
4 |
| Total Buy Transactions |
2 |
2 |
4 |
6 |
| Total Shares Sold |
0 |
0 |
18,000 |
418,803 |
| Total Sell Value |
$0 |
$0 |
$136,018 |
$6,319,950 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
3 |
29 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Monahan Joseph |
Chief Scientific Officer |
• – – |
2023-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
163,761 |
|
- |
|
| Monahan Joseph |
Chief Scientific Officer |
• – – |
2023-03-02 |
4 |
S |
$12.37 |
$183,024 |
D/D |
(14,800) |
151,261 |
|
15% |
|
| Balthaser Kevin |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
6,150 |
|
- |
|
| Balthaser Kevin |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
S |
$12.29 |
$12,289 |
D/D |
(1,000) |
4,650 |
|
15% |
|
| Walker Neal |
Director |
– • – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
138,425 |
1,314,188 |
|
- |
|
| Monahan Joseph |
Chief Scientific Officer |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
74,675 |
166,061 |
|
- |
|
| Balthaser Kevin |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,950 |
5,650 |
|
- |
|
| Monahan Joseph |
Chief Scientific Officer |
• – – |
2023-02-15 |
4 |
AS |
$13.06 |
$65,311 |
D/D |
(5,000) |
91,386 |
|
-26% |
|
| Loerop James |
Chief Business Officer |
• – – |
2023-02-08 |
4 |
S |
$13.89 |
$59,272 |
D/D |
(4,267) |
6,983 |
|
23% |
|
| Walker Neal |
Director |
– • – |
2023-02-02 |
4 |
AS |
$14.57 |
$81,248 |
D/D |
(5,000) |
1,175,763 |
|
-34% |
|
| Walker Neal |
Director |
– • – |
2023-02-01 |
4 |
AS |
$16.75 |
$418,675 |
D/D |
(25,000) |
1,180,763 |
|
-46% |
|
| Loerop James |
Chief Business Officer |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
11,250 |
|
- |
|
| Walker Neal |
Director |
– • – |
2023-01-04 |
4 |
AS |
$14.89 |
$223,343 |
D/D |
(15,000) |
1,205,763 |
|
-44% |
|
| Walker Neal |
Director |
– • – |
2023-01-03 |
4 |
AS |
$15.19 |
$381,213 |
D/D |
(25,000) |
1,220,763 |
|
-48% |
|
| Monahan Joseph |
Chief Scientific Officer |
• – – |
2022-12-15 |
4 |
AS |
$15.88 |
$79,412 |
D/D |
(5,000) |
96,386 |
|
-45% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-11-14 |
4 |
AS |
$17.08 |
$23,417 |
I/I |
(1,371) |
434,455 |
|
-54% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-11-11 |
4 |
AS |
$17.06 |
$702,177 |
I/I |
(41,160) |
435,826 |
|
-52% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-11-10 |
4 |
AS |
$17.02 |
$193,995 |
I/I |
(11,395) |
476,986 |
|
-53% |
|
| Powell Andrew Kenneth William |
Director |
– • – |
2022-11-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
9,856 |
|
- |
|
| Schiff Dr Drew |
Director |
– • – |
2022-10-26 |
4 |
AS |
$17.01 |
$247,253 |
I/I |
(14,540) |
488,381 |
|
-52% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-10-25 |
4 |
AS |
$17.02 |
$204,516 |
I/I |
(12,018) |
502,921 |
|
-54% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-10-24 |
4 |
AS |
$17.01 |
$248,586 |
I/I |
(14,616) |
514,939 |
|
-53% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-10-18 |
4 |
AS |
$16.89 |
$542,022 |
I/I |
(32,093) |
529,555 |
|
-26% |
|
| Monahan Joseph |
Chief Scientific Officer |
• – – |
2022-10-17 |
4 |
AS |
$15.98 |
$79,908 |
D/D |
(5,000) |
101,386 |
|
-24% |
|
| Schiff Dr Drew |
Director |
– • – |
2022-10-17 |
4 |
AS |
$16.05 |
$320,087 |
I/I |
(19,944) |
561,648 |
|
-24% |
|
402 Records found
|
|
Page 3 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (4.49%) 
